{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:28:39Z","timestamp":1790188119700,"version":"4.1.0"},"reference-count":96,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007771","name":"Medical University of Silesia","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100007771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Janus kinase (JAK) inhibitors, a novel class of targeted synthetic disease-modifying antirheumatic drugs (DMARDs), have shown their safety and efficacy in rheumatoid arthritis (RA) and are being intensively tested in other autoimmune and inflammatory disorders. Targeting several cytokines with a single small compound leads to blocking the physiological response of hundreds of genes, thereby providing the background to stabilize the immune response. Unfortunately, blocking many cytokines with a single drug may also bring some negative consequences. In this review, we focused on the activity of JAK inhibitors in the cardiovascular system of patients with RA. Special emphasis was put on the modification of heart performance, progression of atherosclerosis, lipid profile disturbance, and risk of thromboembolic complications. We also discussed potential pathophysiological mechanisms that may be responsible for such JAK inhibitor-associated side effects.<\/jats:p>","DOI":"10.3390\/ijms21197390","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T09:12:58Z","timestamp":1602061978000},"page":"7390","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-6527","authenticated-orcid":false,"given":"Przemys\u0142aw J.","family":"Kotyla","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Rheumatology and Clinical Immunology, Faculty in Katowice, Medical University of Silesia, 40-635 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5937-6473","authenticated-orcid":false,"given":"Md Asiful","family":"Islam","sequence":"additional","affiliation":[{"name":"Department of Haematology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Engelmann","sequence":"additional","affiliation":[{"name":"Department of Physiotherapy in Internal Medicine, Academy of Physical Education in Katowice, 40-065 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s10067-007-0657-3","article-title":"Treatment with infliximab may contribute to the development of peripheral neuropathy among the patients with rheumatoid arthritis","volume":"26","author":"Kotyla","year":"2007","journal-title":"Clin. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kotyla, P.J. (2018). Bimodal function of anti-tnf treatment: Shall we be concerned about anti-tnf treatment in patients with rheumatoid arthritis and heart failure?. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19061739"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s10067-019-04866-x","article-title":"Incidence of tuberculosis in patients receiving anti-tnf therapy for rheumatic diseases: A systematic review","volume":"39","author":"Sartori","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Angelini, J., Talotta, R., Roncato, R., Fornasier, G., Barbiero, G., Dal Cin, L., Brancati, S., and Scaglione, F. (2020). Jak-inhibitors for the treatment of rheumatoid arthritis: A focus on the present and an outlook on the future. Biomolecules, 10.","DOI":"10.3390\/biom10071002"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102390","DOI":"10.1016\/j.autrev.2019.102390","article-title":"Jak inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"106731","DOI":"10.1016\/j.intimp.2020.106731","article-title":"Jak-stat inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis","volume":"86","author":"Singh","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"112155","DOI":"10.1016\/j.ejmech.2020.112155","article-title":"Janus kinases (jaks): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders","volume":"192","author":"Xu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jbspin.2019.09.005","article-title":"Inhibition of jak\/stat signaling in rheumatologic disorders: The expanding spectrum","volume":"87","author":"Jamilloux","year":"2020","journal-title":"Jt. Bone Spine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7492904","DOI":"10.1155\/2018\/7492904","article-title":"Are janus kinase inhibitors superior over classic biologic agents in ra patients?","volume":"2018","author":"Kotyla","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.1073\/pnas.91.14.6374","article-title":"Molecular cloning of l-jak, a janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes","volume":"91","author":"Kawamura","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2008.03.002","article-title":"Cytokine signaling modules in inflammatory responses","volume":"28","author":"Murray","year":"2008","journal-title":"Immunity"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of jak\u2013stat signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4161\/jkst.19418","article-title":"Comparative evolutionary genomics of the stat family of transcription factors","volume":"1","author":"Wang","year":"2012","journal-title":"JAK-STAT"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/08977194.2011.614949","article-title":"Jaks go nuclear: Emerging role of nuclear jak1 and jak2 in gene expression and cell growth","volume":"29","author":"Zouein","year":"2011","journal-title":"Growth Factors"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type i\/ii cytokines, jaks, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00018-015-2062-4","article-title":"The common \u03b3-chain cytokine receptor: Tricks-and-treats for t cells","volume":"73","author":"Waickman","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.cytogfr.2015.07.001","article-title":"Leukemia inhibitory factor (lif)","volume":"26","author":"Nicola","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1097-2765(03)00365-4","article-title":"Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130","volume":"12","author":"Boulanger","year":"2003","journal-title":"Mol. Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2019.03.027","article-title":"Pleiotropy and specificity: Insights from the interleukin 6 family of cytokines","volume":"50","author":"Murakami","year":"2019","journal-title":"Immunity"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ni.2227","article-title":"The composition and signaling of the il-35 receptor are unconventional","volume":"13","author":"Collison","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00251-010-0508-2","article-title":"Two copies of the genes encoding the subunits of putative interleukin (il)-4\/il-13 receptors, il-4ralpha, il-13ralpha1 and il-13ralpha2, have been identified in rainbow trout (oncorhynchus mykiss) and have complex patterns of expression and modulation","volume":"63","author":"Wang","year":"2011","journal-title":"Immunogenetics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The jak-stat pathway: Impact on human disease and therapeutic intervention","volume":"66","author":"Schwartz","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10478","DOI":"10.1074\/jbc.RA120.013935","article-title":"Deciphering site 3 interactions of interleukin 12 and interleukin 23 with their cognate murine and human receptors","volume":"295","author":"Esch","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11926-020-00931-6","article-title":"Jak inhibitors: What is new?","volume":"22","author":"Reddy","year":"2020","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_27","first-page":"553","article-title":"Expression of tyk2 in dendritic cells is required for il-12, il-23, and ifn-\u03b3 production and the induction of th1 cell differentiation","volume":"110","author":"Tokumasa","year":"2007","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"Jaks and stats in immunity, immunodeficiency, and cancer","volume":"368","author":"Holland","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJMoa073687","article-title":"Stat3 mutations in the hyper-ige syndrome","volume":"357","author":"Holland","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMra1100030","article-title":"Genomics and the multifactorial nature of human autoimmune disease","volume":"365","author":"Cho","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ng.625","article-title":"Genome-wide association study identifies variants in the mhc class i, il10, and il23r-il12rb2 regions associated with behcet\u2019s disease","volume":"42","author":"Remmers","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies il23r as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science (N.Y.)"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa073003","article-title":"Stat4 and the risk of rheumatoid arthritis and systemic lupus erythematosus","volume":"357","author":"Remmers","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Alunno, A., Padjen, I., Fanouriakis, A., and Boumpas, D.T. (2019). Pathogenic and therapeutic relevance of jak\/stat signaling in systemic lupus erythematosus: Integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent. Cells, 8.","DOI":"10.3390\/cells8080898"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/ng1097","article-title":"Impaired response to interferon-\u03b1\/\u03b2 and lethal viral disease in human stat1 deficiency","volume":"33","author":"Dupuis","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1172\/JCI37083","article-title":"A partial form of recessive stat1 deficiency in humans","volume":"119","author":"Chapgier","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","article-title":"Interferon target-gene expression and epigenomic signatures in health and disease","volume":"20","author":"Barrat","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/BOR.0000000000000653","article-title":"Interferon-signature in idiopathic inflammatory myopathies","volume":"31","author":"Gallay","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_40","first-page":"185","article-title":"Type i interferon signature in sj\u00f6gren\u2019s syndrome: Pathophysiological and clinical implications","volume":"37","author":"Marketos","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/BOR.0b013e32835c7e32","article-title":"The interferon signature in autoimmune diseases","volume":"25","author":"Eloranta","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12016-020-08798-2","article-title":"Type i interferons in the pathogenesis and treatment of autoimmune diseases","volume":"59","author":"Jiang","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1093\/ndt\/gfn314","article-title":"Activation of signal transducer and activator of transcription 3 correlates with cell proliferation and renal injury in human glomerulonephritis","volume":"23","author":"Arakawa","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_44","unstructured":"Justiz Vaillant, A.A., and Qurie, A. (2020). Interleukin. Statpearls, StatPearls Publishing LLC."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nri2580","article-title":"New insights into the regulation of t cells by \u03b3 c family cytokines","volume":"9","author":"Rochman","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"Il-6: Regulator of treg\/th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"Jak-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s12325-018-0757-2","article-title":"Efficacy of monotherapy with biologics and jak inhibitors for the treatment of rheumatoid arthritis: A systematic review","volume":"35","author":"Emery","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/annrheumdis-2019-216656","article-title":"Efficacy of pharmacological treatment in rheumatoid arthritis: A systematic literature research informing the 2019 update of the eular recommendations for management of rheumatoid arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase iii, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (oral strategy): A phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: Final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3899\/jrheum.161161","article-title":"Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis","volume":"45","author":"Keystone","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"El Jammal, T., S\u00e8ve, P., Gerfaud-Valentin, M., and Jamilloux, Y. (2020). State of the art: Approved and emerging jak inhibitors for rheumatoid arthritis. Expert Opin. Pharmacother., 1\u201314.","DOI":"10.1080\/14656566.2020.1822325"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.12688\/f1000research.12202.1","article-title":"The \u03b3 c family of cytokines: Fine-tuning signals from il-2 and il-21 in the regulation of the immune response","volume":"6","author":"Spolski","year":"2017","journal-title":"F1000Research"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1161\/01.HYP.35.6.1191","article-title":"Cardiotrophin-1 increases angiotensinogen mrna in rat cardiac myocytes through stat3: An autocrine loop for hypertrophy","volume":"35","author":"Fukuzawa","year":"2000","journal-title":"Hypertension"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0092-8674(00)80729-1","article-title":"Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress","volume":"97","author":"Hirota","year":"1999","journal-title":"Cell"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Li, H., Cen, K., Sun, W., and Feng, B. (2020). Predictive value of blood interleukin-6 level in patients with acute coronary syndrome: A meta-analysis. Immunol. Investig., 1\u201313.","DOI":"10.1080\/08820139.2020.1795876"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Xu, L., Yan, J., Zhang, F., Zhou, C., Fan, T., Chen, X., Cui, X., Zhou, H., and Liang, Y. (2020). Use of inflammatory biomarkers and real-time cardiac catheterisation to evaluate the left ventricular diastolic function in patients with diastolic heart failure. Heart Lung Circ.","DOI":"10.1016\/j.hlc.2020.06.017"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: Analyses from the canakinumab anti-inflammatory thrombosis outcomes study (cantos)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Ridker, P.M., MacFadyen, J.G., Glynn, R.J., Bradwin, G., Hasan, A.A., and Rifai, N. (2020). Comparison of interleukin-6, c-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: Secondary analyses from the cardiovascular inflammation reduction trial. Eur. Heart J.","DOI":"10.1093\/eurheartj\/ehaa160"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1536\/jhj.45.183","article-title":"Interleukin-6 and cardiovascular diseases","volume":"45","author":"Kanda","year":"2004","journal-title":"Jpn. Heart J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ejim.2004.07.013","article-title":"Il-6 levels in acute and post myocardial infarction: Their relation to crp levels, infarction size, left ventricular systolic function, and heart failure","volume":"15","author":"Gabriel","year":"2004","journal-title":"Eur. J. Intern. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.3892\/mmr.2020.11266","article-title":"Statin rosuvastatin inhibits apoptosis of human coronary artery endothelial cells through upregulation of the jak2\/stat3 signaling pathway","volume":"22","author":"Wang","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e3196","DOI":"10.7717\/peerj.3196","article-title":"Sevoflurane postconditioning protects the myocardium against ischemia\/reperfusion injury via activation of the jak2\u2013stat3 pathway","volume":"5","author":"Wu","year":"2017","journal-title":"PeerJ"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"9309","DOI":"10.3892\/mmr.2017.7771","article-title":"Promoting effects of il-23 on myocardial ischemia and reperfusion are associated with increased expression of il-17a and upregulation of the jak2-stat3 signaling pathway","volume":"16","author":"Liao","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jacc.2011.10.863","article-title":"Interleukin-17a contributes to myocardial ischemia\/reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil infiltration","volume":"59","author":"Liao","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral janus kinase inhibitor","volume":"46","author":"Wicker","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","article-title":"Impact of janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: Systematic review and meta-analysis of randomised controlled trials","volume":"78","author":"Xie","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/art.40911","article-title":"Risk factors for major adverse cardiovascular events in phase iii and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"71","author":"DeMasi","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/ard.2008.101964","article-title":"Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: A challenge to conventional cardiovascular risk actions","volume":"68","author":"Choy","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/annrheumdis-2013-203293","article-title":"Analysis and modelling of cholesterol and high-density lipoprotein cholesterol changes across the range of c-reactive protein levels in clinical practice as an aid to better understanding of inflammation\u2013lipid interactions","volume":"73","author":"Johnsson","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrrheum.2013.91","article-title":"Changes in lipid levels with inflammation and therapy in ra: A maturing paradigm","volume":"9","author":"Robertson","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/art.38894","article-title":"Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: A systematic review and meta-analysis","volume":"67","author":"Souto","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (option study): A double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/acr.23875","article-title":"Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"72","author":"Singh","year":"2020","journal-title":"Arthritis Care Res."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Castagn\u00e9, B., Viprey, M., Martin, J., Schott, A.-M., Cucherat, M., and Soubrier, M. (2019). Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0220178"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/a-0833-4627","article-title":"Effect of il-6 receptor blockade on proprotein convertase subtilisin\/kexin type-9 and cholesterol efflux capacity in rheumatoid arthritis patients","volume":"51","author":"Machado","year":"2019","journal-title":"Horm. Metab. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.atherosclerosis.2013.04.031","article-title":"Pro-atherogenic lipid changes and decreased hepatic ldl receptor expression by tocilizumab in rheumatoid arthritis","volume":"229","author":"Strang","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Greco, D., Gualtierotti, R., Agosti, P., Adorni, M.P., Ingegnoli, F., Rota, M., Bernini, F., Meroni, P.L., and Ronda, N. (2020). Anti-atherogenic modification of serum lipoprotein function in patients with rheumatoid arthritis after tocilizumab treatment, a pilot study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072157"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/bph.13932","article-title":"Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: Understanding the lipid paradox associated with rheumatoid arthritis","volume":"174","author":"Barrasa","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_84","first-page":"318","article-title":"The mechanism of action of tofacitinib-an oral janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Li, Y., Yuan, L., Yang, J., Lei, Y., Zhang, H., Xia, L., Shen, H., and Lu, J. (2019). Changes in serum cytokines may predict therapeutic efficacy of tofacitinib in rheumatoid arthritis. Mediat. Inflamm., 2019.","DOI":"10.1155\/2019\/5617431"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"D1040","DOI":"10.1093\/nar\/gks1215","article-title":"Interferome v2. 0: An updated database of annotated interferon-regulated genes","volume":"41","author":"Rusinova","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.avsg.2016.05.088","article-title":"Comparison of pathogenic mechanisms underlying single and recurrent venous thromboembolism based on gene expression profiling","volume":"36","author":"Xu","year":"2016","journal-title":"Ann. Vasc. Surg."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.thromres.2014.03.042","article-title":"Role of a janus kinase 2-dependent signaling pathway in platelet activation","volume":"133","author":"Lu","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12288-016-0685-8","article-title":"The impact of mean platelet volume (mpv) and jak-2 mutation on thrombosis in chronic myeloproliferative diseases","volume":"33","author":"Ayer","year":"2017","journal-title":"Indian J. Hematol. Blood Transfus. Off. J. Indian Soc. Hematol. Blood Transfus."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/978-3-030-34521-1_33","article-title":"Heparanase in the coagulation system","volume":"1221","author":"Nadir","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_91","first-page":"616","article-title":"Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib","volume":"67","author":"Fleischmann","year":"2015","journal-title":"Arthritis Rheumatol. (Hoboken N.J.)"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J. Rheumatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.matbio.2013.02.008","article-title":"Versatile role of heparanase in inflammation","volume":"32","author":"Goldberg","year":"2013","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/art.23489","article-title":"Dramatic regulation of heparanase activity and angiogenesis gene expression in synovium from patients with rheumatoid arthritis","volume":"58","author":"Li","year":"2008","journal-title":"Arthritis Rheum. Off. J. Am. Coll. Rheumatol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Ghoti, H., Ackerman, S., Rivella, S., Casu, C., and Nadir, Y. (2020). Heparanase level and procoagulant activity are increased in thalassemia and attenuated by jak-2 inhibition. Am. J. Pathol.","DOI":"10.1016\/j.ajpath.2020.07.011"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00011-019-01293-1","article-title":"Potent repression of c-reactive protein (crp) expression by the jak1\/2 inhibitor ruxolitinib in inflammatory human hepatocytes","volume":"69","author":"Lecureur","year":"2020","journal-title":"Inflamm. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/19\/7390\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:17:06Z","timestamp":1760177826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/19\/7390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":96,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["ijms21197390"],"URL":"https:\/\/doi.org\/10.3390\/ijms21197390","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]}}}